Phase 2Status unknownAge-related condition

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease

Sponsor
Institute for Neurodegenerative Disorders (Academic or other)
Enrollment
3,000 planned
Conditions
Parkinson Disease
Interventions
[123I]β-CIT and SPECT imaging; [123I]β-CIT
Ages
adults, older adults
Registry
NCT00387075

Full record on ClinicalTrials.gov

From the registry

This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD. First-degree relatives of PD will be recruited through PD research sites and national foundations to participate in this study. In addition, first degree relatives of PD patients will be recruited directly through advertising.

Primary outcomes

  • the mean striatal uptake of [123I]B-CIT in first-degree relatives with a loss of odor identification, compared to an established healthy control database (age 40-70; n=50)

History

  1. Primary completion

  2. Last registry update

  3. Started

  4. Registered

Papers citing this trial